The influence of statin medications on prostate-specific antigen levels.
The influence of statin medications on prostate-specific antigen levels.
复制标题
DOI：
10.1093/jnci/djn362
复制
发表时间：
2008-11-05
期刊：
影响因子：
--
通讯作者：
Freedland, Stephen J
中科院分区：
文献类型：
--
作者：
Hamilton, Robert J;Goldberg, Kenneth C;Freedland, Stephen J
背景：最近的数据表明，他汀类药物的使用可能与晚期前列腺癌风险降低有关。然而，他汀类药物对前列腺特异性抗原（PSA）水平的影响以及这对前列腺癌诊断的潜在影响尚不清楚。我们对1214名男性进行了一项纵向研究，这些男性在1990年至2006年期间在达勒姆退伍军人事务医疗中心接受了他汀类药物治疗，他们没有前列腺癌，未接受前列腺手术或服用已知可改变雄激素水平的药物，且在开始他汀类药物治疗前2年内至少有一个PSA值，在开始他汀类药物治疗后1年内至少有一个PSA值。使用Wilcoxon符号秩检验将他汀类药物治疗前后PSA的变化作为连续变量进行分析。使用多元线性回归分析PSA变化与胆固醇参数（低密度脂蛋白[LDL]、高密度脂蛋白[HDL]和总胆固醇）变化之间的相关性。结果：开始使用他汀类药物时的平均（SD）年龄为60.3（8.3）岁;中位前他汀PSA浓度为0.9（1.9）ng/mL;平均前他汀LDL胆固醇浓度为144（34）mg/dL。开始使用他汀类药物后，LDL下降的中位数为27.5%，PSA下降的中位数为4.1%（两种比较均为P <0.001）。PSA浓度的变化与他汀类药物剂量和LDL水平的变化密切相关。开始使用他汀类药物后，LDL每降低10%，PSA水平下降1.64（95%置信区间[CI] = 0.64%至2.65%，p = 0.001）。最有可能考虑进行前列腺活检的男性（prestatin PSA水平>或=2.5 ng/mL，n = 188），LDL下降>41%的患者（最高四分位数）开始使用他汀类药物后，（95%CI = 10.0%~ 24.9%）下降。结论：开始他汀类药物治疗后，PSA水平下降的程度具有统计学意义。这种降低在LDL下降最大的男性和PSA水平使他们成为前列腺活检候选人的男性中最为明显。通过降低PSA水平，他汀类药物可能使癌症检测复杂化，尽管需要进一步研究来量化这种作用的临床意义。
BACKGROUND: Recent data suggest that statin use may be associated with a reduced risk of advanced prostate cancer. However, the influence of statins on prostate-specific antigen (PSA) levels and what effect this could potentially have on prostate cancer diagnosis are unknown.METHODS: We conducted a longitudinal study of 1214 men who were prescribed a statin between 1990 and 2006 at the Durham Veterans Affairs Medical Center who were free of prostate cancer, had not undergone prostate surgery or taken medications known to alter androgen levels and who had at least one PSA value within 2 years before and at least one PSA value within 1 year after starting a statin. The change in PSA from before to after statin treatment was analyzed as a continuous variable using the Wilcoxon signed rank test. The association between change in PSA and change in cholesterol parameters (low-density lipoprotein [LDL], high-density lipoprotein [HDL], and total cholesterol) was analyzed using multivariate linear regression. All statistical tests were two-sided.RESULTS: Mean (SD) age when starting statins was 60.3 (8.3) years; median prestatin PSA concentration was 0.9 (1.9) ng/mL; and mean prestatin LDL cholesterol concentration was 144 (34) mg/dL. After starting a statin, the median LDL decline was 27.5%, and the median PSA decline was 4.1% (P < .001, for both comparisons). Changes in PSA concentration were strongly associated with statin dose and changes in LDL levels. For every 10% decrease in LDL after starting a statin, PSA levels declined by 1.64 (95 % confidence interval [CI] = 0.64% to 2.65%, p = .001). Among men most likely to be under consideration for prostate biopsy (prestatin PSA levels > or =2.5 ng/mL, n = 188), those with >41% declines in LDL (highest quartile) after starting a statin experienced a 17.4% (95% CI = 10.0% to 24.9%) decline in serum PSA.CONCLUSIONS: PSA levels declined by a statistically significant extent after initiation of statin treatment. The reduction was most pronounced among men with the largest LDL declines and those with PSA levels that would make them candidates for prostate biopsy. By lowering PSA levels, statins may complicate cancer detection, although further studies are needed to quantify the clinical significance of this effect.